AMIX AUTONOMIX MEDICAL INC

Autonomix Medical, Inc. to Participate in Virtual Investor Webinar Hosted by Ladenburg Thalmann & Co. Inc.

Autonomix Medical, Inc. to Participate in Virtual Investor Webinar Hosted by Ladenburg Thalmann & Co. Inc.

Live video webcast on Thursday, August 21st at 1:00 PM ET

THE WOODLANDS, TX, Aug. 18, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced that will participate in a on Thursday, August 21, 2025 and 1:00 PM ET.

The webinar will be moderated by Jeffrey S. Cohen, Managing Director and Director of Equity Research of Ladenburg Thalmann. Following the discussion, there will be a question and answer session. Interested participants may pre-submit questions to ahead of the event.

To register for the webinar, please click here. The webinar will also be accessible on the page in the section of the Company’s website ()

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit and connect with the Company on , , and .



Investor and Media Contact

JTC Team, LLC

Jenene Thomas

(908) 824-0775



EN
18/08/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AUTONOMIX MEDICAL INC

 PRESS RELEASE

Autonomix Medical, Inc. to Participate in Virtual Investor Webinar Hos...

Autonomix Medical, Inc. to Participate in Virtual Investor Webinar Hosted by Ladenburg Thalmann & Co. Inc. Live video webcast on Thursday, August 21st at 1:00 PM ET THE WOODLANDS, TX, Aug. 18, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced that will participate in a on Thursday, August 21, 2025 and 1:00 PM ET. The webinar will be moderated by Jeffrey S. Cohen, Managing Director and Director of Equity Research of Ladenburg Thalmann. Following the discussion, th...

 PRESS RELEASE

Autonomix Medical, Inc. to Present at the Webull Financial Corporate C...

Autonomix Medical, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech – Live video webcast on Thursday, August 21st at 2:20 PM ET THE WOODLANDS, TX, Aug. 15, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced that it will present at the being held virtually August 19-21, 2025. Details for the presentation are as follows: Date and Time: Thursday, August 21, 2025 at 2:20 PM ET Presenter: Registration Link: About Webull Financi...

 PRESS RELEASE

Autonomix Medical, Inc. Finalizes Design Review of First-Ever Intravas...

Autonomix Medical, Inc. Finalizes Design Review of First-Ever Intravascular Nerve Sensing Catheter in Key Step Toward U.S. Clinical Studies Microchip-based platform enables real-time nerve mapping and targeted treatment from within the vascular system Continued progress toward submitting Investigational Device Exemption (“IDE”), and if approved, the commencement of U.S. clinical trials to support a De Novo FDA application THE WOODLANDS, TX, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to adva...

 PRESS RELEASE

Autonomix Medical, Inc. Participates in the Virtual Investor “What’s Y...

Autonomix Medical, Inc. Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference – Video webcast now available on-demand  THE WOODLANDS, TX, July 22, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that , participated in the . For the event, Mr. Hauser dove deeper into his dedication to the Company, how he got to where he is today, and provided insight int...

 PRESS RELEASE

Autonomix Medical, Inc. Exercise of Warrants for $2.5 Million Gross Pr...

Autonomix Medical, Inc. Exercise of Warrants for $2.5 Million Gross Proceeds THE WOODLANDS, TX, July 22, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise (or prepayment of the exercise price) of certain outstanding warrants to purchase up to an aggregate of 1,477,596 shares of common stock of the Company originally issued in November 2024 at a reduced exercise pri...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch